SCOTT GREENBERG

Scott is Chief Business Officer of Nura Bio, overseeing business development activities at the company. Scott most recently served as Chief Operating Officer of Aro Biotherapeutics, a biotech company focused on the development of targeted siRNA therapies, where he led fundraising efforts, finance and business development functions as well as corporate strategy, new product planning, and project management. Scott brings more than 20 years of experience in business development, R&D strategy, and management spanning several therapeutic areas holding leadership roles at Roivant Sciences, and Celgene Corporation (acquired by Bristol-Myers Squibb Company). He began his career in investment banking at Goldman Sachs & Co.  

Scott graduated with dual bachelor’s degrees in Finance and Biological Basis of Behavior from the University of Pennsylvania and completed his MBA from Harvard Business School.